GLI1 and breast carcinoma: Expression analysis of key markers of the activity of the HH signaling pathway i.e. GLI1 and PTCH1, revealed higher expression in the tamoxifen resistant LCC2 breast cancer cells compared to the parental, tamoxifen sensitive MCF7 cells (Figure 1A and 1B).